Background:
Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years.
Objective:
To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis.
Eligibility:
People aged 18 years and older with interstitial lung disease or lung fibrosis.
Design:
Participants will have at least 7 clinic visits over 5 months.
Participants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include:
Spirometry: Participants will breathe in and out through a mouthpiece to measure how much air they can hold in their lungs and how hard they can breathe.
Diffusion capacity of lungs for carbon monoxide: Participants will breathe in a gas that contains a small amount of carbon monoxide. Then they will breathe through a mouthpiece. This test measures how well oxygen moves from the air into the blood.
Resting energy expenditure. Participants will lie still for 30 minutes with a clear dome over their head. This test measures the calories their body burns at rest.
6-minute walk test. Participants will walk at their normal pace for 6 minutes. Their vital signs and blood oxygen levels will be checked.
Hymecromone is a tablet taken by mouth. Participants will take 2 tablets every morning and 2 tablets every night for 12 weeks. Tests will be repeated at study visits.

开始日期2025-05-05

申办/合作机构

The National Institute of Environmental Health Sciences

NCT05295680

/ Recruiting临床2期IIT

A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study).

Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care.
To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely: (a) fibrotic effect (FibroScan); (b) inflammatory biomarkers (serum Hyaluronan (HA)); and, (c) T-cell count.

开始日期2023-05-10

申办/合作机构

Stanford University

NCT05386420

/ Unknown statusN/AIIT

A Single-center, Randomized, Parallel Controlled, Double-blind Clinical Trial Designed to Evaluate the Efficacy and Safety of Hymecromone Tablets in Subjects Diagnosed With COVID-19 Infection.

The coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019, which causes epidemic worldwide. A study found that the increase in hyaluronic acid levels is closely related to the clinical symptoms of COVID-19, including pulmonary ground glass lesions, lymphocytopenia, immune response and cytokine storms, systemic vascular diseases, thrombotic coagulation disorders, which suggests that hyaluronic acid could be an important target for COVID-19 treatment and could improve the clinical symptoms of COVID-19 patients.
The results from a recent clinical trial recruited 144 patients with COVID-19 show that the inhibitor of hyaluronic acid synthesis, hymecromone, can significantly improve clinical symptoms, such as lung lesions and lymphocytopenia in COVID-19 patients. Therefore, hymecromone has the potential to become one of the options of COVID-19 treatment.
This study is a single-center, randomized, parallel controlled, double-blind clinical trial designed to evaluate the efficacy and safety of Hymecromone tablets in subjects aged 18-90 years (with boundary values) with a confirmed mild or moderate form of COVID-19 infection. The aim of this study is to optimize the program of the combination of hymecromone in the treatment of COVID-19 to improve the therapeutic effect.

开始日期2022-05-23

申办/合作机构

复旦大学附属中山医院

100 项与羟甲香豆素相关的临床结果

登录后查看更多信息

100 项与羟甲香豆素相关的转化医学

登录后查看更多信息

100 项与羟甲香豆素相关的专利（医药）

登录后查看更多信息

3,328

项与羟甲香豆素相关的文献（医药）

2025-12-01·Natural Products and Bioprospecting

Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy

Article

作者: Liao, Fei ; Wang, Cong ; Gui, Chun ; Xiang, Meixian ; Mei, Hanxiang ; Wang, Yingying ; Deng, Denghui ; Wu, Songtao ; Zheng, Xiang ; Zheng, Guohua

Abstract:

Modern pharmacology has found that both Realgar and Coptis chinensis can induce apoptosis in tumor cells, and traditional Chinese medicine theory suggests the possibility of combining the two, however, the specific mechanisms involved have not been elucidated. This study investigated the therapeutic mechanism of the Realgar-Coptis chinensis drug pair (RCCD) against hepatocellular carcinoma (HCC) by identifying its key active compounds and targets. Through integrated LC–MS analysis, transcriptomics, network pharmacology, and bioinformatics, we identified the mechanism of action, key bioactive compounds, and core targets. Molecular docking, molecular dynamics simulations, and microscale thermophoresis (MST) validated the binding affinity between key compounds and core targets. TIMER2.0 database was used to analyze the relationship between the core targets and HCC. H22 tumor xenograft mouse model and immunohistochemistry and pathology analyses were performed to validate the antitumor efficacy of the active compounds. RCCD has a high degree of selectivity of lipid metabolism pathway, 4-Methylumbelliferone (4-MU) was the key active compound with strong binding activity to the core target fatty acid synthase (FAS), and 4-MU down-regulated the expression of FASN in tumor tissues and induced apoptosis in HCC cells. In addition, as a hyaluronan synthase (HAS2/3) inhibitor, 4-MU interfered with the HA-dependent tumor microenvironment and fibrosis process by inhibiting HAS2/3. Thus, 4-MU may inhibit tumor progression by inhibiting FAS and HAS2/3. 4-MU extracted from RCCD exerts anti-HCC effects by modulating the activities of FAS and HAS2/3, thereby reprogramming lipid metabolism and regulating hyaluronan synthesis.Graphical Abstract

2025-09-15·RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Study of the Photoinduced Fate of Selected Contaminants in Surface Waters by HPLC‐HRMS

Article

作者: Calza, Paola ; Binetti, Rita ; Papagiannaki, Dimitra ; Medana, Claudio ; Sesia, Rossella ; Bello, Federica Dal

ABSTRACT:

Rationale:

Photoinduced transformation of contaminants of emerging concern (CECs) can occur in aquatic environment and could lead to the formation of transformation products (TPs) of greater concern than the parent compounds. For such, the fate of epoxiconazole, hymecromone, and coumarin in water was investigated by simulating photoinduced abiotic transformations to assess the toxicity of their TPs and which CEC may be of greatest concern.

Methods:

Heterogeneous photocatalysis with TiO2 and direct photolysis of selected CECs were exploited to simulate their TPs. The TPs were assessed by means of HPLC coupled with an Orbitrap MS analyser in ESI positive mode, while their toxicity was evaluated through a Vibrio fischeri bioluminescence assay, and ECOSAR tool.

Results:

The formation of numerous TPs via different photoinduced pathways was noticed (27 for epoxiconazole, 6 for coumarin, and 8 for hymecromone, some of which are in the form of structural isomers). Toxicity assessment via V. fischeri assay showed that, unlike coumarin species, epoxiconazole transformation proceeds through the formation of toxic compounds. By means of ECOSAR software, the formation of predominant more noxious TPs of epoxiconazole was proved than the parent compound for both acute and chronic toxicities. Instead, most TPs of coumarin and hymecromone generally exhibited “harmful” and “toxic” levels of acute and chronic toxicities.

Conclusions:

A probable structural identification was assigned to the monitored TPs via HPLC‐HRMS to recognize the several transformation pathways, of which the hydroxylation reaction was predominant, and which compound may be more hazardous in the aquatic system due to its TPs. Epoxiconazole transformation brought to potentially toxic TPs, whereas photoinduced degradation of coumarin and hymecromone resulted in less hazardous TPs. The most significant aspect of this work is the ability of this overall approach to identify the formation of photoinduced TPs that are potentially more toxic than the original CEC.

2025-09-08·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Logic‐Gated Release of a Dual Payload from a β‐Lactam Mechanophore with a Rotaxane Actuator

Article

作者: De Bo, Guillaume ; Chen, Lei

Abstract:

The force‐controlled release of functional molecules has attracted interest due to its potential use in drug delivery and self‐healing applications. Clever mechanochemical devices have been developed to that effect, but most are limited by the payload (type, number) they can deliver and their responsiveness to a single stimulus (force). However, the applications envisaged above require the precise delivery of a complex payload. In this context, a device able to release a diverse set of cargo molecules in response to a varied number of stimuli is desired. Here, we present a rotaxane‐based device that can release a dual payload in response to two different stimuli: force and water. The first payload is released mechanically, while the release of the second cargo requires both force and water in a way reminiscent of a logic AND gate. Our device is built around a β‐lactam mechanophore that is activated by a rotaxane actuator to release a ketene and reveal an imine that anchors the second cargo to the axle of the rotaxane; hydrolysis of the imine releases the second cargo molecule. The concept was demonstrated with the efficient release of two drugs, hymecromone and gemcitabine, both in solution and in bulk. We anticipate that our device should find applications in a variety of contexts where precise release is required.

项与羟甲香豆素相关的新闻（医药）

2025-07-17

·E药经理人

详解国自然民企联合基金申报要点齐鲁制药16个重点支持项目即将开放申报

近日，国家自然科学基金民营企业创新发展联合基金（以下简称“民企联合基金”）正式启动，该基金的项目指南同期发布，引发科研界广泛关注。随着7月30日项目信息系统开放日期的临近，作为首批加入该基金的医药企业之一，齐鲁制药相关负责人就基金研究方向、重点支持的项目、申报要点、申报时间以及注意事项等一系列备受关注的问题作出详细解读。01民企联合基金：首批为何是医药企业加入？6月30日，齐鲁制药等4家医药企业与国自然基金委签约，正式加入民企联合基金，标志着我国民营企业深度参与国家基础研究迈出关键一步。首批为何是4家医药企业加入？国家自然科学基金委党组书记、主任窦贤康此前在接受媒体采访时表示，我国医药领域的民营企业对科技创新的需求非常旺盛，民企联合基金首批选择医药行业作为突破口，就是希望瞄准医药企业真实需求，让中国快速发展的技术力量和基础研究水平赋能这些企业，推动形成一些具有国际竞争力的医药企业。据悉，民企联合基金由国家自然科学基金委和参与的民营企业共同出资，由企业来提出问题，双方成立一个联合专家组确定项目指南的内容。从发布的指南看，首批资助的项目都由企业来“出题”。指南确定后，全国的优秀科研人员都可以竞争来承担相关课题。“以前，企业有需求，但不一定能找到最合适的科学家来完成，科学家有很好的成果，但他们可能不知道企业的需求是什么。”窦贤康说，民企联合基金希望搭建一个让双方顺畅合作的平台。02对话齐鲁制药：聚焦哪些前沿领域？记者梳理发现，指南公布的支持课题项目聚焦生命健康领域，涵盖肿瘤精准治疗、代谢性疾病、神经系统疾病、心血管疾病、新型递药系统等前沿研究方向，充分体现了“临床需求导向”和“技术创新驱动”等特点，重点支持AI辅助分子筛选、双免疫组合抗体、器官芯片等前沿技术在医疗健康领域的应用。“民企联合基金的设立是国家推动科技创新和产业创新深度融合的重要举措，也是对企业创新实力的认可。”齐鲁制药相关负责人表示，作为联合资助方，齐鲁制药与国自然基金委共同投入9900万元，主要聚焦免疫失调、细胞异常增殖、基因突变与表达调控异常、代谢失常及神经系统疾病等领域，支持科学家开展基础研究与应用基础研究。基金采用“企业出题、科学家答题”的协同攻关模式，确保课题既立足科学前沿又紧扣产业发展需求。据介绍，项目指南的形成经过多轮严格论证，首先由企业提出产业关键问题并凝练科学问题，结合发展需求广泛征集需要解决的重大关键问题；随后，国自然基金委相关科学部对年度项目进行审读修改，统筹规划布局，避免重复资助；最后经专家组科学论证，确保指南具有科学性、规范性、包容性、安全性。以齐鲁制药重点支持的项目“抗PD-1/CTLA-4双免疫组合抗体在PD-(L)1单抗耐药宫颈癌患者中的有效性及机制研究”为例，希望通过基础研究，针对宫颈癌PD-(L)1单抗耐药问题提供更多思路和突破。据悉，2025年度民营企业创新发展联合基金以重点支持项目的形式予以资助，资助期限均为4年，直接费用平均资助强度约为220万元/项。03课题申报指南：科研人员需关注的要点对于有意申报的科研人员，民企联合基金齐鲁制药联系人苗菁特别提醒，申请人和依托单位应当认真阅读并执行项目指南、《2025年度国家自然科学基金项目指南》和《关于2025年度国家自然科学基金项目申请与结题等有关事项的通告》中相关要求，严格对照项目指南发布的齐鲁制药16个重点支持项目，及时登录国家自然科学基金网络信息系统，项目采取无纸化申请，申请人在线方式撰写申请书。值得注意的是，申请人应当具有承担基础研究课题或者其他从事基础研究的经历，并具有高级专业技术职务（职称），在站博士后研究人员、正在攻读研究生学位以及无工作单位或者所在单位不是依托单位的人员不得作为申请人进行申请。根据2025年度民企联合基金时间进度安排，申请书提交时间为2025年7月30日至8月5日16时。项目提报后，由国自然基金委科学部组织完成通讯评审，随后召开委内委外联席工作会议；在完成会议评审的基础上，确定最终资助项目清单。随着指南的公布以及申报即将启动，齐鲁制药已开通专项咨询通道（苗菁0531-55820179/李欣0531-55820709），为科研人员提供针对性指导。齐鲁制药期待与包括战略合作伙伴在内的全国科研人员开展深度沟通，携手探索创新解决方案，共同破解医药领域“卡脖子”难题，让更多科研创新成果惠及患者。04齐鲁制药有限公司民企联合基金重点支持项目1.肺纤维化的病理机制及候选药物研究（申请代码1选择H01或H34的下属代码）结合临床数据，探索肺纤维化致病机理，发现并确证相关的药物靶点；结合小分子药物设计或其他药物形式开发靶向药物，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。2.代谢相关功能障碍脂肪性肝炎（MASH）的病理机制及候选药物研究（申请代码1选择H03或H34的下属代码）结合临床数据，探索MASH致病机理，发现并确证相关药物靶点；结合小分子药物设计或其他药物形式开发靶向药物，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。3.AI辅助的代谢疾病相关GPCR偏向性调节剂的发现（申请代码1选择H07或H34的下属代码）针对代谢疾病中GPCR偏向性调节剂的筛选难题，开展AI辅助的GPCR偏向性调节剂的从头设计与虚拟筛选，构建基于AI分子生成及多维度成药性评估与分子优化的体系，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。4.AI辅助的神经系统疾病相关GPCR偏向性调节剂的发现（申请代码1选择H09或H34的下属代码）针对神经系统疾病中GPCR偏向性调节剂的筛选难题，开展AI辅助的GPCR偏向性调节剂的从头设计与虚拟筛选，构建基于AI分子生成及多维度成药性评估与分子优化的体系，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。5.难治性疼痛的发病机制及候选药物研究（申请代码1选择H09或H34的下属代码）针对带状疱疹后神经痛、糖尿病周围神经病、三叉神经痛等难治性疼痛，结合临床数据，发现并确证相关药物靶点；结合小分子药物设计或其他药物形式开发靶向药物，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。6.卒中发病机制及候选药物研究（申请代码1选择H09或H34的下属代码）针对卒中，结合临床数据，发现并确证相关药物靶点；结合小分子药物设计或其他药物形式开发靶向药物，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。7.抑郁症的发病机制及候选药物研究（申请代码1选择H10或H34的下属代码）针对抑郁症药物起效延迟和反复发作难题，结合临床和多组学数据，探索其致病机理，发现新靶点；结合小分子药物设计或其他药物形式，开发快速起效的靶向药物，并通过体内外模型评价治疗效果和初步安全性，获得至少1个有知识产权的候选分子。8.基于类器官模型的肝癌耐药机制研究及应用（申请代码1选择H18或H34的下属代码）针对肝癌具有高度异质性和耐药问题，建立不少于50个肝癌患者来源的类器官，通过空间组学及分子可视化等技术筛选20个以上的膜表达肿瘤相关蛋白，揭示其时空异质性与变化规律，并结合上述已建立的类器官模型解析常见治疗药物及ADC毒素的耐药特征及分子机制，确认候选治疗靶点或组合2-3个。9.基于难治性肺癌队列空间组学研究的新靶点发现与应用（申请代码1选择H18或H34的下属代码）针对小细胞肺癌耐药后难治的问题，建立不少于50例具有空间组学数据的难治性肺癌队列和不少于20例的类器官或PDX模型，发现至少3个肿瘤相关膜蛋白靶点，研究其时空异质性规律和调控机制，设计具有知识产权的抗体或ADC候选分子至少1个，通过体内外模型评估其抗肿瘤效果和安全性。10.基于难治性头颈鳞癌队列空间组学研究的新靶点发现与应用（申请代码1选择H18或H34的下属代码）针对头颈鳞癌耐药后难治的问题，建立不少于50例具有空间组学数据的难治性头颈鳞癌队列和至少20例的类器官或PDX模型，发现至少3个肿瘤相关膜蛋白靶点，研究其时空异质性变化规律和调控机制，设计具有知识产权的抗体或ADC候选分子至少1个，通过体内外模型评估其抗肿瘤效果和安全性。11.基于难治性三阴乳腺癌队列空间组学研究的新靶点发现与应用（申请代码1选择H18或H34的下属代码）针对三阴乳腺癌耐药后难治的问题，建立不少于50例具有空间组学数据的三阴乳腺癌队列和至少20例的类器官或PDX模型，发现至少3个肿瘤相关膜蛋白靶点，研究其时空异质性变化规律和调控机制，设计具有知识产权的抗体或ADC候选分子至少1个，通过体内外模型评估其抗肿瘤效果和安全性。12.基于耐药结直肠癌生物样本库的新靶点发现及应用（申请代码1选择H18或H34的下属代码）建立不少于100例的常规治疗耐药或术后复发的生物样本库和至少50个来源于患者的类器官或异种移植模型。利用空间转录组等多组学技术，鉴定至少3个肿瘤相关耐药靶点，并解析其在肿瘤内的异质性特征和时空演进规律。设计小分子或其它药物形式，并获得至少1个有知识产权的候选分子。13.抗PD-1/CTLA-4双免疫组合抗体在PD-(L)1单抗耐药宫颈癌患者中的有效性及机制研究（申请代码1选择H18的下属代码）针对宫颈癌PD-(L)1单抗耐药问题，建立不少于50例的患者队列，评估抗PD-1/CTLA-4双免疫组合抗体在该人群中的疗效，通过构建高质量生物样本库，并采用多组学整合分析与功能验证的研究方法，鉴定双免疫组合抗体在PD-(L)1单抗耐药人群中有效应用的核心分子特征及关键调控机制。14.蛋白多肽药物新型口服递送系统的效应及机制研究（申请代码1选择H34的下属代码）针对蛋白多肽药物口服吸收生物利用度低的难题，设计具有显著增强其口服吸收效率的新载体及递送系统，探索载药系统结构组成与消化道跨膜吸收效率的构效关系及其影响因素，获得至少一种具有转化前景的蛋白多肽药物口服递送系统。15.小核酸药物肝外靶向新型递送技术的研究（申请代码1选择H34的下属代码）针对小核酸肝外靶向递送的技术壁垒，研发安全高效的新型肝外递送系统，提升小核酸的治疗效能，重点针对肺、肾等组织进行递送载体的开发和验证，建立具有自主知识产权的递送技术。16.非肿瘤适应症新型ADC药物机制研究及应用（申请代码1选择B07的下属代码）针对自身免疫性疾病、神经退行性疾病等重大慢性疾病，设计并探索新型ADC药物靶向递送新机制，研究载荷分子设计与筛选，微环境响应型连接技术开发，获得至少1个有知识产权的候选ADC药物。一审| 黄佳二审| 李芳晨三审| 李静芝

基因疗法

2024-10-14

·米内网

【市场】葵花药业入局23亿大品种

精彩内容近日，葵花药业以仿制4类提交的熊去氧胆酸胶囊上市申请获得CDE承办。米内网数据显示，2023年中国三大终端六大市场熊去氧胆酸胶囊销售额超过23亿元。熊去氧胆酸是一种亲水性、非细胞毒性的胆汁酸。熊去氧胆酸胶囊适用于：（1）胆囊胆固醇结石——必须是 X 射线能穿透的结石，同时胆囊收缩功能须正常；（2）胆汁淤积性肝病（如：原发性胆汁性肝硬化）；（3）胆汁反流性胃炎。米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）熊去氧胆酸胶囊销售额超过23亿元。其中，原研厂家Dr. Falk占据的市场份额超过70%，首仿厂家安士制药占比12%。中国三大终端六大市场熊去氧胆酸胶囊销售情况（单位：万元）来源：米内网格局数据库国内市场已有6家企业的熊去氧胆酸胶囊获批上市，包括Dr. Falk、安士制药、宣泰医药、赛璟生物、广生堂、绍兴来多科技等。熊去氧胆酸胶囊中国获批情况来源：米内网中国上市药品（MID）数据库在胆疾病治疗药物方面，葵花药业已有中成药复方胆通片、利胆排石片、利胆片及化学药羟甲香豆素片等产品获批上市。若熊去氧胆酸胶囊顺利获批上市，将进一步丰富公司产品种类。资料来源：米内网数据库、CDE注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

100 项与羟甲香豆素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00170	羟甲香豆素	A05AX02	DB07118

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胆道疾病	-	-	2025-05-13
胆汁淤积	-	-	-
痉挛	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特发性肺纤维化	临床2期	美国	HALO BIOSCIENCES, INC.	2025-05-05
原发性硬化性胆管炎	临床2期	美国	Stanford University	2023-05-10
原发性硬化性胆管炎	临床2期	美国	HALO BIOSCIENCES, INC.	2023-05-10
肺性高血压	临床2期	美国	HALO BIOSCIENCES, INC.	-
呼吸系统疾病	临床1期	美国	Stanford University	2020-12-01
心肌缺血	临床前	伊朗	Iran University of Medical Sciences & Health Services	2024-01-06
再灌注损伤	临床前	伊朗	Iran University of Medical Sciences & Health Services	2024-01-06
肝细胞癌	临床前	意大利	Fondazione Italiana Endometriosi Onlus	2023-04-20
脑疾病	临床前	法国	Saur SAS	2022-11-16
多发性硬化症	药物发现	美国	Stanford University School of Medicine	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05128929 (Pubmed \| Thorax)	临床2期	肺性高血压 hyaluronan (HA)	16	Hymecromone	糧築觸製淵構範夢齋顧(衊網製構範衊範齋膚鹽) = 觸遞窪獵簾夢淵艱衊膚膚醖鏇壓觸壓繭壓鹹淵 (鹹選積夢夢夢鑰壓鏇醖, -1.5 ~ 2.7) 更多	积极	2025-09-01
NCT05128929 (The SATURN Study \| SATURN, CTgov)	临床2期	肺动脉高压 \| 间质性肺疾病 \| 肺性高血压	17	H01 (Experimental Treatment Oral Hymecromone (H01))	鏇顧獵簾窪廠壓蓋醖簾(選壓鬱夢構選鑰襯齋淵) = 製餘願糧積蓋構遞積鏇夢廠夢願網願鹹網襯醖 (築壓願膚壓簾鹹蓋憲鏇, 2.65) 更多	-	2024-11-26
NCT05128929 (The SATURN Study \| SATURN, CTgov)	临床2期	肺动脉高压 \| 间质性肺疾病 \| 肺性高血压	17	Placebo (Placebo)	鏇顧獵簾窪廠壓蓋醖簾(選壓鬱夢構選鑰襯齋淵) = 衊衊鏇觸範醖鹽鑰鑰衊夢廠夢願網願鹹網襯醖 (築壓願膚壓簾鹹蓋憲鏇, 4.16) 更多	-	2024-11-26